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   Many Breast cancer patients treated with chemotherapy have suffered from chemotherapy 
induced cognitive dysfunction (CICD). Studies in rats show that Erk and Akt pathways were 
increased upon treatment of chemotherapy. Erk and Akt are involved with normal aging of the 
brain and its increase hints to the source of cognitive impairment. The field of epigenetics is just 
beginning to surface so studying the epigenetic implications of chemobrain is reasonable. The 
goal of this study was to analyze common epigenetic markers and their implications in 
chemobrain. The prefrontal cortex (PFC) of rats with intact ovaries were used. Using RT-PCR 
and Western blot analysis, we have analyzed common epigenetic markers such as DNA 
Methyltransferase 1 (DNMT1), DNA Methyltransferase 3a (DNMT3a), Methyl-CpG binding 
protein 2 (Mecp2), CREB binding protein (CBP), and Ten-Eleven translocase 1 (Tet1). Differential 
expression of these markers between control and rats treated with chemotherapeutic drugs 
was observed. Chemotherapy treatment consisted of a cocktail containing doxyrubicin and 
cyclophosphamide, chemotherapeutics typically used for breast cancer and found to cause 
chemobrain. DNMT1, Tet1, CBP, and Mecp2 showed no statistically significant change in 
expression between saline and chemotherapy treated rat PFC. DNMT3a expression in rat PFC 
was found to increase with chemotherapy treatment. Global DNA methylation and 
hydroxymethylation assays were performed to determine the level of methylated DNA. There 
was no statistically significant change in DNA methylation levels and DNA hydroxymethylation 
levels between saline and chemotherapy treated rats. These results indicate epigenetic 




Introduction   
   Breast cancer is the most common cancer worldwide. Survival rates vary between regions of 
the world with a 5-year survival rate at 80% in high income countries and about 40% in low 
income countries.1 There are several risk factors involved in the development of breast cancer 
including age, family history, and environmental factors. For example, 1:202 women from birth 
to age 39 will likely develop the disease compared to 1:26 women from 40-59 years. However, 
the detection of breast cancer has significantly improved over the years and has resulted in 
earlier detection of breast cancer. Imaging such as MRI, ultrasounds, and yearly mammograms 
are integral parts of cancer diagnosis.2 
Thankfully, the life span of breast cancer patients has increased over the past number of years. 
Research is now being shifted towards long term effects of chemotherapy. Specifically, it has 
been previously reported that upon treatment of chemotherapeutic drugs such as doxorubicin 
and cyclophosphamide, patients experienced cognitive decline in the form of memory loss and 
learning impairment.3 These two drugs are used commonly for breast cancer patients.4 
According the American Society of Clinical Oncology, Chemobrain effects nearly 75% of patients 
treated with chemotherapy for breast cancer. This loss of memory and inability to perform 
certain tasks that were once easy has become terrifying to patients suffering from chemobrain. 
Patients become less efficient at work, forget important things like looking at a stop light, or get 
lost while driving. Performing everyday tasks become a great burden.5 Some doctors did 
address the possibility of chemobrain but never knew when or if patient’s cognition would 
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improve. Chemobrain is a dangerous effect of chemotherapy and is fortunately becoming a 
major focus of study. Discovering the mechanism behind chemotherapy induced cognitive 
decline can help improve the quality of life for patients diagnosed with breast cancer.  
   This study aims to analyze common epigenetic markers to observe their role in the 
development of cognitive impairment following treatment of the chemotherapeutic drugs, 
doxorubicin and cyclophosphamide.  Epigenetics literally translates as “Above” genetics in 
Greek referring to the layer of gene expression outside of the 4-nucleotide genetic code. 
Specifically, DNA is coiled around proteins called histones in part of a greater process of 
condensing the long DNA into a small nucleus.6 DNA wrapped around these proteins are known 
as nucleosomes. Histones consist of four proteins in duplicate and are H2A, H2B, H3, H4, and 
one H1 protein to hold the nucleosome together. These proteins have tails attached consisting 
of amino acids that can be chemically modified. DNA wrapped tightly around histones are 
normally associated with genes that are silenced as transcription factors cannot access the DNA 
properly. However, DNA loosely wrapped around histones can have transcription factors bind 
to it activating associated genes. Histones have a positive charge because of the protein side 
chains allowing it to bind to negatively charged DNA. Certain modifications can take place on 
the histones to modify its binding on the DNA either activating genes or deactivating them. 
   DNA Methylation  
   One epigenetic mechanism takes place on the DNA itself. Specifically, cytosine can be 
methylated mostly when it is in a CpG site (Cytosine-Phosphodiester bond-Guanine).7 
Methylated cytosines recruit a protein known as Mecp2 which functions to silence genes.8 This 
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is done in one of two ways. Mecp2 can sterically block transcription factors from binding to 
DNA. Mecp2 can also recruit proteins that modify and compact chromatin. As such, DNA 
methylation results in silencing of genes. However, new studies are revealing that Mecp2 can 
act as an activator of gene expression by recruiting transcription factors such as CREB.9 The 
proteins responsible for this methylation are DNA Methyltransferase 1 (DNMT1) and DNA 
Methyltransferase 3A (DNMT3A).7 DNMT1 is responsible for the maintenance of the 
methylation pattern upon DNA replication. When the DNA is replicated, the methylation 
pattern is not copied to the daughter strand. DNMT1 copies the methylation pattern of the 
parent strand to that newly formed strand. DNMT3A adds methyl groups to cytosines not 
previously methylated. This is important at the blastocyst stage of development after the 
methylation pattern of the parents have been stripped off.10 Altered patterns of DNA 
methylation have been linked to the onset of cancer by silencing tumor suppressors.11  
   Until recently, methylation of cytosines was thought to be a permanent modification. 
(Tahiliani et.Al) found that wild type, but not mutant TET1-CD (Cytosine rich and DSBH regions) 
in Sf9 insect cells catalyzed conversion of 5mc to 5 hMc.12 This modification has been shown to 
be linked to re-activation of the gene that was previously silenced by methylation. The proteins 
responsible for this conversion is the Ten-eleven-translocation enzymes (TET).12 The 
hydroxymethylated cytosine is converted to 5-formylcytosine (5fC), then to carboxylcytosine 





Histone Acetylation  
The Histones can be modified on their tail extensions protruding from the protein core.14 
Histone acetyl transferases (HATs) add an acetyl group to lysine residues on the tails of 
histones.15,17 The addition of an acetyl group lessens the positive charge on the histone 
essentially lessening the attraction between the negatively charged DNA. This loose 
confirmation of the nucleosome allows DNA to be targeted by transcription factors and as a 
result, histone acetylation is always involved with gene activation. Histone deacetylases can 
reverse this process by removing the acetyl group from the histones.16 This will result in the 
formation of heterochromatin and gene silencing.15                                                  
Histone methylation 
Histone tails can also be methylated on their lysine or arginine residues in H3 or H4 proteins.17 
This modification can be involved with either gene expression or gene silencing depending on 
the amino acid methylated and how many methyl groups are added. Lysine or arginine residues 
can be methylated up to three times.18 This modification is also reversible by histone 
demethylases but only on the lysine residue.19 Methylation on the arginine residue has yet to 
be found as reversible.20    
   Cognition 
   The broad definition of cognition is the action of gaining knowledge through experiences, the 
senses, and thought. This includes, memory, working memory, learning, problem solving, 
judgement, and knowledge.21 We have analyzed two regions of the brain responsible for 
certain specific behaviors and processes. Hippocampus dependent processes have already been 
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shown to be affected by chemotherapy by us and the lab.3 The hippocampus is primarily 
responsible for the consolidation of short-term memory to long term memory, and in spatial 
navigation.22 The prefrontal cortex covers the front part of the frontal lobe.23 The prefrontal 
cortex is primarily responsible for executive functions such as differentiating conflicting 
thoughts.24 It is also shown to play an important role in memory retrieval making it a good 
region to study when analyzing cognitive impairment.25   
   Chemobrain 
   Upon treatment of cyclophosphamide and doxorubicin, chemotherapeutic drugs used to treat 
breast cancer in women, patients have been affected by cognitive dysfuntion.3 Rats treated 
with doxorubicin and cyclophosphamide showed significant cognitive decline when they were 
ovariectomized. The purpose of removing the ovaries is to eliminate the possibility of estrogen 
playing any type of role in cognition. This essentially mimics a post-menopausal female.26 To 
test for working memory, rats treated with saline and chemotherapy were subjected to the Y-
maze test.3 Rodents tend to visit novel places and will only visit one arm of the maze once, then 
move to the next arm. That was seen in saline treated rats but not in chemotherapy treated 
rats. Treated rats showed significantly lower spontaneous alternation regardless if they were 
ovariectomized or intact. The study showed a decrease in working memory in rats treated with 
chemotherapy.3 Spatial memory, also being hippocampus dependent, was also analyzed. There 
was a decreased ratio of time spent exploring the new location of the object by the time spent 
exploring objects on the object placement task, showing that animals treated with 
chemotherapy have decrease spatial memory.3 The behavior was independent of hormonal 
status.3 Upon treatment, there was significant increase in Erk 1/2 and Akt pathways normally 
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involved in regular aging of the brain. This study showed that these drugs can potentially 
advance the cellular aging process of the brain resulting from oxidative stress. Premature 
cellular aging has been speculated to be caused by oxidative stress that takes place upon 
treatment.27 Oxidative stress increases pro inflammatory cytokines and it has been shown that 
epigenetic changes are associated with the increase expression of pro inflammatory 
cytokines.28 Studies have shown that women with cognitive dysfunction after treatment have 
different leukocyte methylation patterns compared to before treatment.29 In summary, there is 
reasonable evidence that treatment by chemotherapy does cause cognitive decline.    
   Chemotherapy  
   Chemotherapeutic drugs have already been shown to cause epigenetic changes. Treatment of 
two cancer cell lines CEM-Bcl2 and SW620 with chemotherapeutic drugs daunorubicin (DNR) 
and etoposide (ETOP) caused increase expression of MDR1 gene.30 MDR1 gene is responsible 
for chemotherapy resistance in cancer patients.31 Treatment of these chemotherapeutic drugs 
in the mentioned cancer cell lines showed decrease of MDR1 promoter DNA methylation. As 
methylation of DNA is associated with silencing of associated genes, decrease in methylation is 
associated with activation.8 Also, there was an increase in H3K4 methylation associated with 
hyperacetylation at the promoter of MDR1 which indicates activation.32 These modifications 
caused the abnormal increased expression of MDR1 gene in the cancer cell lines.  
   Another study showed that treatment of bleomycin, etoposide, and cis-platinum (BEP) 
chemotherapeutic drug used to treat testicular cancer, altered epigenetic modifications in the 
sperm DNA.33 Rats treated with BEP showed a dose dependent hypermethylation of 20 loci in 
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germ cells. Many of these loci are hypermethylated even at low doses of chemotherapy 
showing that some loci are more sensitive to chemotherapy than others. Most of these loci are 
involved in important cell signaling pathways such as RefSeq gene Cpne8 in calcium mediated 
intracellular processes and RefSeq gene Slc16a2 in transport of the thyroid hormone. The 
increase in methylation means that these genes are abnormally repressed when the rats were 
treated with BEP. Also, a number of these genes are involved in tumor growth and invasion 
(RefSeq gene table). Alteration of the methylation patterns of these genes could affect germ 
cell development of the father and, as a result, have an impact on future progeny. These 
studies demonstrate that chemotherapy induces epigenetic modifications critical to normal 
biological functions.   
   A study evaluated the link prior chemotherapy treatment with changes in DNA methylation 
patterns that can explain persistent inflammation and fatigue.34 Before radiation therapy, DNA 
was extracted from peripheral blood mononuclear cells (PBMCs) of 61 stage 0 IIIA breast cancer 
patients. These patients have received partial mastectomies with or without chemotherapy. 
DNA methylation was assessed at 485,000 CpG sites across the genome. Included were markers 
previously shown to be associated with inflammation and fatigue. Patients who received 
chemotherapy showed decrease methylation in 8 CpG sites compared to the non-treated 
counterpart. Four of these differentially methylated CpG sited are on exon 11 of 
transmembrane protein 49 (TMEM49), which functions to permit transport of specific 
molecules. This decrease in methylation of these CpG sites was associated with increase of pro 
inflammatory cytokine IL-6 as well as soluble tumor necrosis factor receptor. These results 
linked chemotherapy treatment to increase in inflammatory biomarkers. Six months post 
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radiation therapy, pro inflammatory markers were once again analyzed. There was still reduced 
methylation of 4 of the original 8 CpG sites and was associated with increase of the previously 
mentioned pro inflammatory cytokines. This study indicates the epigenetic changes that take 
place upon treatment of chemotherapy and indicates the reversible nature of some of these 
changes.  
   A recent study sought to analyze the effects of cytotoxic chemotherapeutic drugs mitomycin C 
(MMC) and cyclophosphamide.35 Alterations in the transcriptome and epigenetic modifications 
in the mouse prefrontal cortex and the hippocampus, were assessed. Gene expression changes 
in response to treatment was found to be largely in females and specific to the prefrontal 
cortex of the brain 3 weeks after treatment.35 Also, MMC seemed to alter gene expression 
more than cyclophosphamide. Treatment of MMC resulted in oxidative DNA damage as shown 
by the increase of 8-oxo-2’-deoxyguanosine (8-OxodG) 3 weeks after treatment. There was also 
a decrease in an 8-OxodG repair protein. Treatment with MMC also decreased global DNA 
methylation and increased global DNA hydroxymethylation in the female mouse prefrontal 
cortex. Most of the changes that took place in the PFC of female mice due to chemotherapy 
were similar to the changes that occur during normal aging. This study indicates that the effect 
of chemotherapy on epigenetic processes in the brain mimics aging in the brain.    
   Epigenetics and the brain 
    It has already been extensively studied that epigenetics plays a significant role in cognition. 
One such study showed that fear conditioning induces changes in H3K4 trimethylation 
(associated with activation) and H3K9 dimethylation (associated with repression) in specific 
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areas of the hippocampus.36 Histone 3 methylation on Lysine 4 (associated with transcription) 
was analyzed 1 hour after fear conditioning. An increase in H3K4 trimethylation patterns was 
seen in the hippocampus compared to the control group. Fear conditioning is a test for learning 
and creating new memories.37 They also analyzed the H3K9 di-methylation patterns (associated 
with silencing) in the hippocampus. An hour post fear conditioning, western blots revealed an 
increase in H3K9 di-methylation patterns. This shows that active repression is involved in 
memory formation. This study helps support the hypothesis that histone methylation plays a 
critical role in memory formation.  
   Another study measured mRNA levels of DNMT3A and DNMT3B.38 Adult rats were put 
through fear conditioning tests. Using real-time qPCR, they looked at DNMT levels in the CA1 
region of the hippocampus. DNMT3A and DNMT3B mRNA levels increased within 30 minutes of 
fear conditioning compared to the control group not exposed to the shock. Immediately after 
fear conditioning, distinct DNMT inhibitors 5-aza-deoxycytidine (5-AZA) or zebularine (zeb) 
were infused into the CA1 region of the hippocampus. 24 hours after infusion, memory was 
tested. Rats treated with DNMT inhibitors showed significantly less freezing showing that 
DNMT3A and DNMT3B were necessary for memory formation. However, once the inhibitor 
clears the hippocampus, the animals can resume normal memory formation suggesting that the 
change in methylation patterns is not permanent, but reversible. This study suggests that DNA 
methylation plays a significant role in memory formation.  
   Epigenetic mechanisms have been shown to modulate cognitive dysfunction in many 
neurodegenerative diseases such as Alzheimer’s.39 In this research, a blockade in gene 
expression was observed in the neurodegenerating brain. This was in large part due to the 
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histone deacetylase 2 which, as its name suggests, deacetylates histones and deactivates gene 
expression.40 Histone deacetylase 2 was found to be significantly increased in patients with 
Alzheimer’s disease as well as two mouse models of neurodegeneration.40,41 The genes that are 
silenced as a result of histone deacetylase 2 activity are those that are involved in learning and 
memory. Importantly, knocking down histone deacetylase activity using short hairpin RNA will 
reverse the repression of these genes making them once again, active.39 This increases synaptic 
plasticity and decreases memory impairment caused by neurodegeneration. This study suggests 
the important role of epigenetic mechanisms in normal and abnormal brain function.  
   Neuronal function of euchromatin histone methyltransferase (EHMT) has been evaluated in 
Drosophila.42 EHMT is a conserved protein that methylates histone 3 lysine 9 as a repressive 
mark and silences transcription. Although widely expressed in the nervous system, two EHMT 
mutant flies are viable. These mutants are null deletions in the p element of the 5’ UTR.  
Analysis of neurodevelopment and behavior revealed an important role of EHMT in courtship 
memory and on associative learning. Memory was restored when expression of EHMT was 
restored in adults. This indicates that the memory impairment caused by loss of EHMT is 
reversible. Using ChIP-seq analysis, the authors analyzed the H3K9 dimethylation profiles. There 
was a loss of H3K9 dimethylation in EHMT mutants in about 5% of euchromatin. This loss is also 
associated with genes involved with neuronal and behavioral functions that are affected in 
EHMT mutant flies. This study has effectively identified the role of EHMT in cognitive functions 
such as learning and memory. This also demonstrates the importance of epigenetics in brain 




   Epigenetics and chemobrain   
   Epigenetic modifications have been shown to be a significant factor in the development of 
chemobrain. Rats were subjected to water maze tests in order to assess spatial learning and 
long-term memory of a specific location.43 Rats were either treated with saline as a control or 
with a combination of three chemotherapy drugs; cyclophosphamide, methotrexate, and 5-
fluorouracil. Treated rats had longer swim latencies and paths than saline rats. However, 
eventually the chemotherapy treated rats performed about the same as saline treated rats by 
day 4 of the trial.43 The study showed that this combination of drugs leads to impairment in 
spatial learning and long-term memory. Using BrdU, they were also able to observe a decrease 
in cell proliferation in the hippocampus of rats treated with chemotherapy compared to saline 
treated rats. Looking at histone modification, they discovered that histone acetylation on H3 of 
the hippocampus and prefrontal cortex was significantly increased in rats treated with 
chemotherapy. Also, HDAC activity was decreased in treated rats. These are surprising results 
as histone acetylation is usually associated with enhanced learning and memory.39 These results 
indicate that chemotherapy does induce epigenetic changes in the brain.  
   Furthermore, it has been shown that Chronic Kidney Disease (CKD) patients with marks of 
inflammation such as IL-6 (Interleukin-6) had DNA hypermethylation in peripheral blood 
leukocytes.44,45 Normally, chemotherapeutic drugs cannot cross the blood brain barrier. 
However, studies show that pro inflammatory cytokines such as interlukin-1 (IL-1), interlukin-6 
(IL-6) and tumor necrosis factor-alpha (TNFalpha) can cross the blood brain barrier.46 Cytokine 
dysregulation is seen in patients experiencing chemobrain.47 As mentioned regarding CKD 
inflammation, there is an increase in methylation patterns. Previous studies show that 
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increases in pro inflammatory cytokines has the potential to induce epigenetic changes.28 Using 
this information, it therefore is reasonable to assume the increase of proinflammatory 
cytokines induced by chemotherapeutic drugs will cause hypermethylation of the brain as well.     
   Along similar lines, a study was done to determine the effects of chemotherapy exposure of a 
father on his transgenerational progeny’s brains.48 Male mice were treated with three 
chemotherapeutic drugs (cyclophosphamide (CPP), procarbazine (PCB) and mitomycin C 
(MCC)). DNMT1 levels and Mecp2 levels were found to be reduced in the frontal cortex of the 
progeny brain. Low levels of DNMT1 means lower levels of critical methylation in the 
transgenerational chemotherapy exposed brain.49 Mecp2 has been shown to be required for 
genome stability and maintaining neuronal networks.50 These results indicate that altered 
methylation in chemotherapy exposed brains can lead to cognitive dysfunction in the progeny 
of patients treated with chemotherapy. 
   These previous studies show that chemotherapy treatment post cancer results in epigenetic 
modifications that can cause cognitive dysfunction. The limited amount of study done in this 
area, as well as the surfacing knowledge of epigenetics, makes this work a reasonable focus of 
research. 
AIM 1  
    In order to determine whether CICD is modulated by epigenetic mechanisms, we measured 
the protein expression of well characterized biomarkers; CBP, DNMT1, DNMT3a, Mecp2, and 
Tet1 in rats treated with chemotherapy and rats treated with saline. The model that was used 
in this experiment were Sprague Dawley female rats (n=26: 12 saline and 14 chemo) as the 
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chemotherapeutic effects on their brains has already been studied. Rats are larger in size than 
mice making them easier to handle. The physiology of rats is also like that of humans and has 
been used as models for disease.51  
      It was expected that a decrease in the DNMTs would be seen in chemotherapy treated rats 
against saline treated rats. This is because previous work showed that Erk and Akt pathways are 
activated after chemotherapy treatment so a decrease in repressing factors such as DNMTs 
would have been reasonable. This would align with the fact that proteins involved in aging of 
the brain have increased expression.3 It was expected that CBP will have no change in 
chemotherapy versus saline treated rats. This is because CBP induces the expression of the 
neuroprotective protein Brain-derived neurotropic factor (BDNF) and BDNF levels stay the same 
between the two experimental groups.3 Tet1 was expected to increase in expression in rats 
treated with chemotherapy as DNMTs decrease. This would align with the expected increase in 
gene expression of proteins involved in cellular aging of the brain. Mecp2 was expected to 
decrease in rat prefrontal cortex treated with chemotherapy as Mecp2 is responsible for 
maintaining neuronal networks.50,55 
 AIM 2 
   The next step was to analyze the DNA methylation patterns between the two experimental 
groups to determine a possible difference in methylation levels. We expected to see a decrease 
of global methylation in chemotherapy treated rats consistent with the predicted decrease of 
DNMTs. However, it would be difficult, if not impossible, to determine the genes effected by 




   As we analyzed patterns of methylation, the next step was to determine the global 
hydroxymethylation using a similar method as shown for Global 5-mc.  
   We expected to see a global increase in hydroxymethlyation in chemotherapy treated rats. 
This assumption was reached because as mentioned in the previous section, Tet1 conversion of 
5-mC to 5hmC is associated with gene activation. As genes involved in brain aging are activated 
upon treatment of chemotherapy, it was expected to see an increase in activating factors such 
as hydroxymethylation. This would be consistent with Western blot data mentioned above. 
Also, as before, it is impossible to determine genes involved with this change from global 
hydroxymethylation data. As a result, a good next step would be to use oxidative bisulfite 
sequencing to determine genes linked to change in hydroxymethylation levels. 
Methods 
  Treatment: Female rats at around 9 weeks of age were treated with a cocktail containing 
chemotherapeutic drugs cyclophosphamide and doxyrubicin (40 mg/kg) or with saline as a 
control, once per week for three weeks. Once per week injections will give the rats time to 
recover from the chemotherapy treatment. One week was allowed for recovery before 
sacrifice. Hippocampus and Prefrontal cortex were removed and frozen at -80⁰C 
   Protein isolation: Extraction of Cytoplasmic and Nuclear fractions was performed (Saline; n=12 
Treated; n=14 on same day) using NE-PER Nuclear and Cytoplasmic extraction reagents from 
Thermo Scientific. One quarter of the PFC of intact rats brain were used in the following 
protocol. 1% of Phosphatase inhibitors and protease inhibitors were added to the Cytoplasmic 
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Extraction Reagent I (CERI) and Nuclear Extraction Reagent (NER) before starting the procedure. 
Tissues from each sample were weighed to be 100 mg and amount of each reagent to be added 
were calculated. Using the manufacturer’s protocol each tube received 321.54 ul CERI, 17.685 
ul Cytoplasmic Extraction Reagent II (CERII), and 160.77 ul NER in total. The tissues were 
washed in Phosphate-Buffered Saline (PBS) and centrifuged for 5 minutes at 500 x g. 
Supernatant was then removed leaving the pellet as dry as possible. Tissues were homogenized 
in the correct amount of CERI buffer. Each tube was vortexed for 15 seconds on highest setting 
to suspend the pellet. They were then incubated on ice for 10 minutes. Next, ice cold CERII was 
added to each sample tube, vortexed for 5 seconds on highest setting, and incubated on ice for 
1 minute. Sample tubes were vortexed again for 5 seconds on the highest setting and 
centrifuged for 5 minutes at maximum speed. Supernatant containing cytoplasmic extract was 
removed and stored in -80 C˚. The pellet was suspended in NER buffer and vortexed for 15 
seconds. The samples were placed on ice and vortexing continued every 10 minutes for 15 
seconds for a total of 40 minutes. Samples were centrifuged at maximum speed for 10 minutes 
and the supernatant was transferred to clean tubes. Nuclear fractions were stored in -80 C˚ 
   Protein quantification: PierceTM BCA Protein Assay Kit was used to quantify protein 
concentration of all samples (done on same day). Protein reduce Cu2+ to Cu1+ in alkaline 
medium. Using a unique reagent containing bicinchoninic acid, a purple color change will take 
place because of chelation of two BCA molecules to one cuprous ion. The intensity of the color 
change is proportional to the protein concentration in the sample. The 96 well plate is put into 
a spectrophotometer to quantify the protein concentration based on color Standards were 









Table 1: Preparation of the standard curve 
The working reagents were prepared by adding 50 parts of BCA reagent A to 1-part BCA reagent 
B. 25 microliters of each standard or sample were added into a microplate well. Unknowns were 
done in duplicates. 20 ul of the working reagent were added into each loaded well and mixed for 
30 seconds. Plate was covered with parafilm and incubated at 37 C˚ for 30 minutes. Absorbance 
was read at 562 nm on the Specramax M5 plate reader. Adjusted concentration was determined 
by the machine.  
   Western Blot: Before beginning the western blot procedure, calculations were performed to 
ensure the same amount of protein (30 mg) from each sample would be added in to each well. 
This was done in the following way; 20ul of total solution would be added to each tube. 5.1 ul of 
sample buffer (Alfa Aesar Laemmli Sodium Dodecyl Sulfate (SDS) sample buffer 4X), Lysis buffer 
(1X RIPA), and lysate. The number of micrograms of protein to be used divided by the adjusted 
concentration multiplied by 1000. This gives the amount of lysate needed. Multiply that by 1.02 
to account for pipetting errors. 15 minus the amount of lysate gave the amount of lysis buffer to 
add. That number was also multiplied by 1.02 for pipetting error. The total volume was slightly 
above 20 ul. The solution was then heated to 98 C˚ for 5 minutes using the Techne TC-312 
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thermocycler. On any given day, six of the saline samples and seven of the chemotherapy treated 
samples were added to one gel to ensure daily consistency.  
   Nuclear fractions were prepared as described above. Thermo Broad range or High range spectra 
ladder were run alongside the prepared samples in an acrylamide gel all in running buffer. 
Running buffer contained 100 ml of 10x Tris-Glycine, 20 ml 10% SDS, and 890 ml dH2O. The gel 
ran at 150 volts for 1 hour or until the blue loading line was just at the bottom of the gel. The 
separated proteins were transferred to a PVDF membrane for 90 minutes at 100 volts. Transfer 
buffer consisted of 100 ml 10x Tris-Glycine, 200 ml methanol and 700 ml dH2O. The membrane 
was activated in methanol for 1 minute before the transfer was set up. Membranes were blocked 
in 5% Bovine Serum Albumin (BSA) for 1 hour at room temperature to reduce non-specific 
binding. Primary antibody incubation was done overnight in the cold room of 4 C˚ using 5% BSA, 
0.1% tween 20, and one of the following; 1:500 rabbit anti-DNMT1, 1:500 rabbit anti-DNMT3a, 
1:1000 rabbit anti-Lamin b, and 1:1000 rabbit anti-Mecp2. Membranes were washed 4 times for 
five minutes each with wash buffer (999 ml 1x TBS and 1 ul of tween 20). Secondary antibody 
incubation was done for 1 hour at room temperature and contained 5% BSA, 0.1% tween 20, and 
1:3000 anti-rabbit HRP (horseradish peroxidase)-conjugated antibody. 4 washes with wash buffer 
for five minutes followed the secondary antibody incubation. Chemiluminescent substrate from 
Pierce was added to the membranes (Protein side) and allowed to incubate for 5 minutes at room 
temperature. The fluorescent signal was detected using Thermo Scientific CL-Xposure film and 
the resulting bands were analyzed using imageJ software.  
DNA Isolation: QIAamp® Fast DNA Tissue Kit was used to isolate the DNA fraction from the brain 
tissue. Tissues from each sample was cut and weighed to be between 5-25 mg and was placed in 
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disruption tubes. As per manufacture’s protocol, 200ul of AVE buffer, 40 ul of VXL buffer, 1 ul of 
DX reagent, 20 ul of proteinase K, 4 ul RNase A were all added to each tube. The tubes were 
vortexed at full speed for 5 minutes to homogenize the tissues. The samples were placed in the 
New Brunswick Scientific incubator shaker at 500 RPM for 20 minutes at 56 C˚ 265 ul Buffer MVL 
was added to each sample and mixed by vortexing. The mixture was added to the spin columns 
provided and centrifuged for 1 minute at full speed. The columns were then placed in clean 
collection tubes and the tubes containing the filtrate were discarded. 500 ul of buffer AW1 was 
added to each sample spin column and were centrifuged for 30 seconds at full speed. The 
collection tubes were discarded and 500 ul of buffer AW2 was added to the spin columns. The 
columns were centrifuged for 30 seconds at full speed and the collection tubes were discarded. 
New collection tubes were added, and the tubes were centrifuged for 2 minutes. The collection 
tubes were discarded and replaced by microcentrifuge tubes. 100 ul of ATE were added to the 
spin columns, incubated at room temperature for 1 minute, and centrifuged for 1 minute at full 
speed. The DNA concentration was then analyzed using the Thermo Scientific Nanodrop 2000.   
   Global DNA Methylation: MethylFlashTM Global DNA Methylation (5-mC) ELISA Easy Kit 
(Colorimetric) from Epigentek was used to measure global 5-mC. First, 1 ul of PC solution was 
diluted in 9 ul of Negative Control (NC) solution to make diluted PC. Standard curve is prepared 
by adding a specific amount of Positive Control (PC), diluted PC, and NC to make the following 
percent of PC/well; 0.1%, 0.2%, 0.5%, 1.0%, 2.0%, and 5.0%. For the negative control, 100 ul of 
Binding Solution (BS) buffer was added to the strip wells and 2 ul of NC. For positive control, 100 
ul BS buffer was added into its respective wells and 2 ul of PC at different concentrations (0.1%-
5%) to generate the standard curve. For the samples (All 26 samples were used on the same 
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plate), 100 ul of BS buffer was added along with 100 ng of sample DNA. The plate was tapped 
gently to ensure the bottom of the substrate containing well was coated with solution. It was 
covered in parafilm and incubated at 37 C˚ for 60 minutes. Each well was then washed with 
diluted wash buffer three times. The remaining wash buffer was emptied and 50 ul of the 5-mC 
Detection Complex Solution (Containing 1 ml diluted wash buffer, 1 ul mcAB, 1 ul of SI buffer, 
and 0.5 ul of Enhancing Solution (ES) buffer) was added to each well. The wells were incubated 
at room temperature for 50 minutes. The 5-mC detection solution was emptied and the wells 
were washed five times with the wash buffer. 100 ul of Developer Solution (DS) solution was 
added to each well in a vertical fashion using a multipipette and color changes were observed. 
After 10 minutes, 100 ul of Stop Solution (SS) buffer was added to each well in the manner and 
the plate was read in the Specramax M5 plate reader at 450 nm. Calculations were performed to 
get the percentage 5-mC.  
   Global DNA Hydroxymethylation:  MethylFlash™ Global DNA Hydroxymethylation (5-hmC) 
ELISA Easy Kit (Colorimetric) was used to measure global 5-hmC. First, 1 ul of PC solution was 
diluted in 9 ul of NC solution to make diluted PC. Standard curve is prepared by adding a specific 
amount of PC, diluted PC, and NC to make the following percent of PC/well; 0.01%, 0.04%, 0.10%, 
0.20%, 0.40%, and 1.0%.  For the negative control, 100 ul of BS buffer was added to the strip wells 
and 2 ul of NC. For positive control, 100 ul BS buffer was added into its respective wells and 2 ul 
of PC at different concentrations (0.02%-1%) to generate the standard curve. For the samples (All 
26 samples were used on the same plate), 100 ul of BS buffer was added along with 100 ng of 
sample DNA. The plate was tapped gently to ensure the bottom of the substrate containing well 
was coated with solution. It was covered in parafilm and incubated at 37 C˚ for 60 minutes. Each 
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well was then washed with diluted wash buffer three times. The remaining wash buffer was 
emptied and 50 ul of the 5-hmC Detection Complex Solution (Containing 1 ml diluted wash buffer, 
1 ul hmcAB, 1 ul of SI buffer, and 0.5 ul of ES buffer) was added to each well. The wells were 
incubated at room temperature for 50 minutes. The 5-hmC detection solution was emptied and 
the wells were washed five times with the wash buffer. 100 ul of DS solution was added to each 
well in a vertical fashion using a multipipette and color changes were observed. After 10 minutes, 
100 ul of SS buffer was added to each well in the manner and the plate was read in the Specramax 
M5 plate reader at 450 nm. Calculations were performed to get the percentage 5-hmC. 
RNA Isolation: RNA isolation was done using RNeasy Mini Kit from Qiagen. 30 mg of rat PRC 
samples were weighed and homogenized in 60 ul of RLT buffer. 600 ul of 70% ethanol was added 
and mixed well by pipetting up and down. 700 ul of the samples were transferred to included 
spin columns and centrifuged at 8000 x g for 15 seconds. The flow through was then discarded 
and new collection tubes were added. 700 ul of RW1 buffer was added to each spin column and 
centrifuged for 15 seconds at 8000 x g. The flow through was discarded. 500 ul buffer RPE was 
added to each spin column and centrifuged for 15 seconds at 8000 x g. Flow through was 
discarded. 500 ul buffer RPE was added to each spin column and centrifuged for 2 minutes at 
8000 x g. Flow through was discarded and 1.5 ml collection tubes were placed on the spin 
columns. 50 ul of RNase-free water was added to each spin column and centrifuged for 1 minute 
at 8000 x g to elute the RNA. RNA concentration was determined using the Thermo Scientific 
Nanodrop 2000. RNA was stored in -80˚C until use.  
cDNA Synthesis: The Thermo Scientific Verso cDNA Synthesis Kit was used to reverse transcribe 
2 ug of RNA to cDNA. 2 ug of RNA (six saline and six chemotherapy treated) was prepared by 
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diluting the RNA in a specific amount of Diethyl Pyrocarbonate (DEPC) treated water such that 2 
ul of RNA would be 2 ug. 2 ul of RNA of each sample were first heated to 65 C˚ for 5 minutes in a 
thermocycler. A master mix was prepared in which each 2 ul of diluted RNA would receive 8 ul of 
5X RT buffer, 1.33 ul Random hexamers, 0.67 ul Anchored oligo dT primers, 4 ul dNTPs, 2 ul RT 
enhancer, and 2 ul of Verso enzyme. The master mix was then added to the post-heated RNA. 
The resulting mixture underwent cDNA synthesis in a thermocycler at 42 C˚ for 45 minutes, then 
2 minutes of inactivation at 95 C˚. The cDNA was stored in -80˚C until use.  
RT-PCR: PowerUp SYBR Green Master Mix from applied biosystems was used for RT-PCR. A 
master mix was made so that each well received 1X SYBR Green master mix solution, 1 ul of 10 
um forward primer, 1 ul of 10 um reverse primer, and 6 ul of DEPC treated water. However, for 
18S, only 0.5 ul of each primer was added and 7 ul of DEPC treated water. Primers used were 
from Invitrogen and are listed in (table 2). 18 ul of the master mix was added to each wells on a 
96 well PCR reaction plate along with the 2 ul of each cDNA sample (six saline and six 
chemotherapy treated). cDNA was not placed in wells assigned for negative control. Samples 
were added in duplicate and ThermoScientific optical adhesive film was added to the top of the 
plate. The plate was placed in the Biosystems 75000 real-time PCR software system after set-up. 
The cycling settings were set to 95 C˚ melting temperature for 15 seconds, annealing temperature 
3-5 C˚ below the melting temperature of primers for 1 minute. It was then heated to 72 C˚ for 1 
minute before heated up to the melting temperature. The total amount of cycles was 40. 
Amplification was monitored as comparative Ct values. Data was analyzed and presented as 













Table 2: List of primers used for RT-PCR 
 
Results 
Chemotherapy induced changes in expression of different epigenetic markers 
   To test the effect of chemotherapy on epigenetic modifiers, expression of DNMT3a, DNMT1, 
and Mecp2 were determined by western blot analysis. The bands were quantified and arranged 
graphically. There was no statistically significant change in DNMT1 expression upon treatment 
of chemotherapy (Figure 1a). However, there was a statistically significant increase in DNMT3a 
(140%) expression upon chemotherapy treatment (Figure 1b). Mecp2 expression showed no 
statistically significant change in Mecp2 expression upon chemotherapy treatment (Figure 1c). 
CBP and Tet1 were assessed using RT-PCR. The RT-PCR data showed that the expression of CBP 
and Tet1 remained unchanged rats treated with chemotherapy compared to controls. (Figure 





Chemotherapy induces changes in global DNA methylation and hydroxymethylation  
Global DNA methylation and hydroxymethylation levels were also analyzed. There was no 
statistically significant change in 5-mC and 5-hmC levels in the chemotherapy treated rats 






















Figure 1: Western Blot analyses of protein expression in PFC of chemo and saline treated rats. Graphically shown 
on the left and the bands are shown on the right. Error bars represent standard error. Saline (n=12) and chemo 
















































































Figure 2: RT-PCR analysis of CBP and Tet1 in the PFC of treated and control rats. Error bars indicate 
standard error. Chemo n=12, Saline n=12. Unpaired t-test; CBP p=0.3648 (NS), Tet1 p=0.4981 (NS) 
 
 









Figure 3: Global DNA methylation and hydroxymethylation in PFC of saline and chemo treated rats.. 



















































































   Specific chemotherapy treatments have been shown to cause cognitive decline in breast 
cancer patients. This study analyzed epigenetic implications in the development of 
chemotherapy induced cognitive decline post doxorubicin and cyclophosphamide treatment. 
Epigenetic markers include; DNMT1, DNMT3a, Mecp2, CBP, and Tet1.  
DNMT1 
   DNMT1 is a DNA methyl transferase responsible for methylating cytosines on DNA in a 
manner that maintains the pattern of the parent strand during replication (Figure 4).7 This will 
ensure proper methylation throughout further generations of the DNA. Methylation of 
cytosines has a repressive effect on the genes associated with it.8 Mecp2 will be recruited to 
the methylated cytosine which will inhibit transcription of the gene either by sterically not 
allowing transcription factors to bind, or by recruiting proteins that modify and compact 
chromatin.8 As such, this is a protein that is important to study as genes such as Erk and Akt are 
misregulated after treatment with chemotherapy.3 The results showed no statistically 
significant change in DNMT1 protein expression in chemotherapy versus control samples. A 
decrease in DNMT1 expression was expected as less DNMT1 would perhaps indicate less 
methylation, fitting with the known increase of ERK and AKT.  
   Previous studies have analyzed the effects of chemotherapy on DNMT1.53 Bcl-2/E1B 19-kDa 
interacting protein 3 (BNIP3) is a proapoptotic protein with often low expression in colorectal 
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cancer.53 This is because of increased methylation of the gene promoter. It is known that the 
combination of chemotherapy and radiation induce apoptosis in colorectal cancer cells, but the 
molecular mechanism is unknown.54 Treatment of colon cancer cells with chemotherapy (5-
fluorouracil, oxaliplatin, and irinotecan) and radiation increased expression of proapoptotic 
protein BNIP3.53 The chemotherapy treatment also decreased the expression of DNMT1 even 
without the radiation therapy. This study can indicate that chemotherapy decreases the 






ZF-CxxC domain-containing proteins, CpG islands and the chromatin connection: Hannah K. Long, Neil P. Blackledge, Robert J. Klose 
Figure 4 shows the activity of DNMT1. DNMT1 acts at the replication fork and ensures that the correct pattern of 
DNA methylation is carried over to the next generation strand 
 
DNMT3a 
   DNMT3a is a protein involved with de novo methylation (Figure 5).7 This means that cytosines 
can be methylated by these proteins independent of their parent strand of DNA. Our results 
showed a slight but statistically significant increase (140%) of DNMT3a protein expression in 
chemotherapy treated rat brains versus control rat brains. This result is interesting as data from 
Fathema Uddin, a former student in the lab, showed a decrease of DNMT3a protein expression 
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in ovariectomized rats treated with chemotherapy compared to ovariectomized controls (Uddin 
and Hubbard, unpublished data). The difference may be explained by the presence of estrogen. 
Nevertheless, this global increase of DNMT3a expression perhaps suggests the inhibition of 
specific genes that are yet to be determined.  








                                                                                        The Molecular Basis of Cancer (Fourth Edition), 2015 
Figure 5 shows the activity of DNMT3a. DNMT3a methylates cytosines in the CpG islands in the 
promoter of genes. This results in silencing of the associated gene. Also shown is the activity of 
Tet1 enzyme that converts methylated cytosine to hydroxymethylated cytosine to reactivate 
the gene. 
 
Mecp2   
   Mecp2 as mentioned earlier, is a protein that is responsible for the silencing of genes (Figure 
6).8 Mecp2 will bind to methylated cytosines and inhibit transcription by either sterically not 
allowing transcription factors to bind, or by recruiting proteins that modify and compact 
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chromatin.8 Our data suggested no statistically significant change in Mecp2 expression in 
chemotherapy treated rat PFC versus controls.  
  Kovalchuk A et. Al (2016) showed that treatment of chemotherapeutic drugs 
(cyclophosphamide, procarbazine, and mytomycin c) results in a decrease expression of Mecp2 
in the subject progeny.48 Mecp2 is essential for maintaining neuronal networks and brain 
anatomy.55 Neurological diseases such as Rett syndrome involve a mutation of Mecp2.56 It 
might be reasonable to assume that rats treated with chemotherapy resulting in chemobrain, 
would have a similar decrease in Mecp2. However, figure 6 above showed otherwise. Kovalchuk 
A et. Al (2016) used treated male mice then mated with untreated females and the brains of 
the one-week old progeny were then analyzed. However, female intact rats were used in this 
experiment. Perhaps the presence of estrogen had a different effect on Mecp2. The effects on 
Mecp2 need to be further studied.    






            Linking Epigenetics to Human Disease and Rett Syndrome: The Emerging Novel and Challenging Concepts in MeCP2 Research Fig 1 





   CREB binding protein is a coactivator that positions histone acetyltransferases near associated 
nucleosomes.57 As such, CBP is involved with the activation of genes.15 One of these genes 
known to be activated by CBP is BDNF, a protein involved in growth and maintenance of 
neurons.58 We have previously shown that the expression level of BDNF does not change 
between control and treated of intact rats or ovariectomized rats.3 However, between intact 
and ovariectomized, BDNF levels increase significantly.3 This change can be caused by the stress 
of removing the ovaries. As BDNF levels do not change between saline and chemotherapy 
treated rats, it would be expected that CBP expression levels do not change either. In figure 2, 
we observed no statistically significant change of CBP. This trend perhaps ties in with previous 
BDNF data but not with other CBP target genes. One such gene is the pro inflammatory 
cytokine TNF-Alpha.59 Perhaps an increase of CBP in chemotherapy treated rat’s PFC would lead 
to an increase in TNF-Alpha and, as mentioned earlier, the increase of pro inflammatory 
cytokines can have effects on epigenetics. As mentioned earlier, peripheral blood leukocytes 
with increase pro inflammatory cytokines had global DNA hypermethylation.44,45   
   This data from CBP is also not in line with previous data. Results by Fathema Uddin 
(unpublished data) showed that there was a significant decrease in CBP between control and 
chemotherapy treated in the prefrontal cortex of ovariectomized rats. This makes sense as CBP 
mediates adult neurogenesis, a decrease of CBP when treated with chemotherapy would 
indicate decrease neurogenesis resulting in cognitive decline. The data observed here showed 
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no statistically significant change in CBP upon chemotherapy treatment. This may be due to the 
presence of estrogen in intact animals.   
   As previously mentioned, Creb binding protein acts as a histone acetyltransferase57 and is 
associated with the activation of genes15. We therefore attempted to analyze the histone 
acetyltransferase activity in chemotherapy treated rat PFC and controls. However, the data was 








Epigenetic histone acetylation modifiers in vascular remodelling: New targets for therapy in cardiovascular disease fig 2 
Figure 7 shows the activity of CBP. CBP acts as a coactivator and has histone acetyltransferase 
activity. This function allows it to activate target genes such as inflammatory cytokine TNF-








   As previously mentioned, Tet1 is involved with the reactivation of genes previously silenced 
by DNA methylation (Figure 5).12 In the qRT-PCR results, no statistically significant change in 
Tet1 RNA expression was observed in the PFC between saline and chemotherapy treated rats. 
This is not in line with expectations as an increase in Tet1 would lead to an increase in 5-hmC 
activating factors, in line with known increased ERK and AKT. Oxidative bisulfite sequencing 
would give us a better understanding as to which genes are affected by a possible change on 5-
hmC levels not detected in this study.   
   However, recent studies have found negative correlations between Tet1 expression and 5hmC 
levels.61 When studying Tet1 and Tet2 expression in aging mice hippocampus, it was found that 
there was an increase in 5hmC but decrease in Tet1. As TET1 levels increase, 5hmC levels 
decrease. The negative correlation can be because Tet1 converts 5mC to hmC which is in turn 
further converted to 5CaC.12    
Global DNA methylation/hydroxymethylation 
   The results for Global DNA methylation showed no observed statistically significant change in 
DNA methylation in chemotherapy treated rats (Figure 3). This is perhaps not in line with 
DNMT3a expression increase in chemotherapy treated rats. However, there are other DNMTs 
that function to methylate DNA besides DNMT3a, the presence of which can affect 5-mC levels. 
Which genes were affected are unknown, however, further work such as oxidative bisulfite 
sequencing would determine the genes being affected by a possible change in methylation not 
observed in this study.62  
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   A recent study showed that DNMT3a and TET1 compete to regulate the epigenetic landscape 
of mouse embryonic stem cells.63 DNMT3a seems to be enriched at distant promoters but not 
proximal promoters where Tet1 exhibits binding. Deletion of Tet1 generated an increase in 
DNMT3a1 binding at genes where wild type Tet1 was found. However, deletion of DNMT3a had 
an insignificant effect on Tet1 binding showing that Tet1 can protect DNA from methylation by 
preventing DNMT3a from binding.  
  Global DNA hydroxymethylation results indicated no observed statistically significant change 
in  DNA hydroxymethylation in chemotherapy treated rat PFC. Hydroxymethylation as 
mentioned earlier, is an oxidation step that takes place on methylated cytosine to return the 
modified cytosine to its original unmodified state.12 This will reactivate transcription and the 
gene associated with it.12 No observed change in hydroxymethylation could perhaps be in line 
with the Tet1 data. Once again, which genes were affected by a possible change in DNA 
hydroxymethylation is unknown as this is a global DNA analysis. Further work such as oxidative 
bisulfite sequencing will determine the genes being affected by a possible change in 5-hmC not 
observed in this study.  
   Future Direction  
   It would be a good next step to look at the activity of HDAC in the chemobrain and perhaps 
inhibiting it. Previous studies do indicate that inhibiting HDAC can have the same results as 
enhancement environments in mice that underwent neurodegeneration.52 In said study, 
treatment of HDAC inhibitors increases histone acetylation, leads to recovery of long-term 
memories, and reinstates the learning ability of mice. It would therefore be interesting to see if 
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treatment of HDAC inhibitors to patients suffering from chemobrain would reverse the effects 
and restore normal cognitive function.    
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